RaQualia Pharma [4579]

Pipelines

Updated on 11 17, 2018

Completed
On planning
On going
Launch
Plan
Project Compound
(Generic name)
Indication Partnered party Discovery Pre-Clin, Clinical Studies NDA Approval Sales Territory Remarks
Phase 1 Phase 2 Phase 3
PotassiumCompetitive acid blocker
(P-CAB)
RQ-00000004
(Tegoprazan)
CJ-12420 [CJ HealthCare]
LXI-15028 [Luoxin Pharma]
RE/NERD -
Completed P1
USA
Japan
RE/NERD CJ HealthCare
Approval (July 2018)
Launch
2019
Korea Product name: K-CAB
Blockbuster expectation with annual sales of 100 billion won.
On going P3
China Re-contracted: CJ HealthCare => Luoxin Pharma
Market Size (China): 260 billion yen (2 billion 600 million USD) *Investigation of RaQualia
On planning P1
ROW ROW: Latin America, East European, Middle East
Taiwan
Southeast Asia
Related information
TRPM8 blocker RQ-00434739 Neuropathic pain -
On planning
Japan
P2X7 receptor antagonist RQ-00466479
AKP-23494954 [Asahi Kasei Pharma]
Neuropathic pain Asahi Kasei Pharma
On going
Global Diabetic neuropathic medicine, herpes virus infective neuropathic medicine. It is conducting tests to establish long-term toxicity tests and industrial synthesis methods. Clinical trial schedule for people in 2019. [Reference]
Selective sodium channel blocker - Analgesia
Pruritus
Maruho
On going
Global
- Pain -
Discovery
Japan
Ion channel - Gastrointestinal EA Pharma
On going
Japan
Sodium channel Nav1.7 selective blocker RQ-00488738 Pain - - Product of collaboration with XuanZhu Pharma
protein-protein interaction inhibitor On Identity Test Pain Interprotein
On going
Japan
5-HT4 partial agonist RQ-00000010 Gastroparesis
Functional dyspepsia
Chronic Constipation
-
Completed P1
UK Mosapride's sales amount of peak tops is 21.2 billion yen (Japan)
Gastroparesis -
Investigator Clinical Trial
USA Collaboration with Virginia Commonwealth University (VCU) Parkinson's and Movement Disorders Center
RQ-00000009
AAT-009 [AskAt]
Alzheimer AskAt Global
5-HT2B antagonist RQ-00310941 IBS-D -
Completed P1
UK
Motilin receptor agonist RQ-00201894 Gastroparesis
Functional dyspepsia
Post - operative Ileus
-
Completed
Japan
Ghrelin receptor agonist RQ-00000005
(Capromorelin)
AT-002 [Aratana]
Weight loss, Anorexia: Dog Aratana Therapeutics
(Global (Animal))
Launch (October 2017)
USA Product name: Entyce®
Approval (2018)
Launch
2019
Europe
Weight loss, Anorexia: Cat
Long term toxicity test
USA
RQ-00433412 Anorexia associated with cancer -
On planning
Japan
Ziprasidone RQ-00000003
(Ziprasidone Hydrochloride Monohydrate)
ME2112 [Meiji Seika Pharma]
Schizophrenia, Bipolar disorder Meiji Seika Pharma
On going P3
NDA
2019
Launch
2020
Japan Market Size (Japan): 160 Billion Yen *Investigation of RaQualia
EP4 antagonist RQ-00000007
(Grapiprant)
AAT-007 [AskAt]
AT-001 [Aratana]
ARY-007 [Arrys]
Osteoarthritis: Dog Aratana Therapeutics
(Global (Animal))
Launch (January 2017)
USA Product name: Galliprant®
With this product Aratana makes strategic alliance with Elanco
Approval (January 2018)
Launch
2018
Europe
MSS Colorectal Cancer AskAt
(Global (Excluding animal))
USA Re-contracted: AskAt => Arrys Therapeutics (Global excluding China and Taiwan)
Development: Arrys affiliate Kyn Therapeutics
Clinical study with grapiprant in combination with pembrolizumab(anti PD-1 antibody, KEYTRUDA).
NSCLC Adenocarcinoma
Cancer
On going P1
China Re-contracted: AskAt => Ningbo Tai Kang Medical Technology
Development: Ningbo NewBay Medical Technology
Pain
Completed P2a
USA
On going P1
China Re-contracted: AskAt => RMX Biopharma
RQ-00000008
AAT-008 [AskAt]
AT-019 [Aratana]
Animal AskAt
(Global)
Development started (2018)
Global Re-contracted: AskAt => Aratana
Cancer
On planning P1
USA Re-contracted: AskAt => Arrys Therapeutics (Global excluding China and Taiwan)
China Re-contracted: AskAt => Ningbo NewBay Medical Technology
COX-2 Inhibitor RQ-00317076
AAT-076 [AskAt]
Acute Pain AskAt
(Global)
Completed P2a
USA
On planning P1
China Re-contracted: AskAt => RMX Biopharma

Other Pipelines

Updated on 3 3, 2018

Project Indication Partnered party Territory Remarks
CB2 antagonist AskAt
Dalbavancin MRSA Infections - Japan US product name: Dalvance
Anidulafungin Candida Infections - Japan US product name: Eraxis

Other Contracts

Updated on 12 15, 2018

Contractor Contract contents Remarks
H. Lundbeck A/S
(Denmark)
RaQualia Grants Patent License to H. Lundbeck Press release
Shire AG
(Swiss)
RaQualia Grants a Non-Exclusive Patent License to Shire AG For the Use of Ghrelin Receptor Agonist Press release
- RaQualia Pharma Joins DeNA & DeNA Life Science AI-Powered Drug Discovery Research Collaboration Press release

University Collaborative Research

Updated on 10 4, 2018

RaQualia Pharma Industry-Academia Collaborative Research Center

University Department Research theme Remarks
Nagoya University Department of Biochemistry, Graduate School of Medicine Exploration of selective blockers targeting specific enzymes for treatment of refractory neuroblastoma Press release
Department of Pathology and Biological Responses, Graduate School of Medicine Exploration of selective blockers targeting connective tissue growth factors (CTGF) for treatment of malignant mesothelioma Press release
Department of Nephrology, Internal Medicine, Graduate School of Medicine Exploration of small molecule compounds inducing the secretion of cytokines and growth factors from adipose-derived stem cells Press release
Department of Cardiovascular Medicine Exploration of selective blockers targeting specific proteins for treatment of cardiac failure Press release
Graduate School of Medicine, Respiratory Internal Medicine Development of novel therapeutic drugs for mutant KRAS lung cancer using cellular senescence Press release
Department of Biochemistry, Graduate School of Medicine Exploration of selective blockers targeting specific enzymes for nerve regeneration Press release
Institute of Environmental Medicine, Molecular metabolism medicine field Collaborative research on nonalcoholic steatohepatitis (NASH) remedy Press release
Institute of Environmental Medicine, Brain functional field Collaborative research on TRPM8 blocker medicine Press release
Gifu Pharmaceutical University Biological function analysis course Pharmacological analysis laboratory Collaborative research on glaucoma remedy Press release

TMRC (subsidiary) Pipeline

Updated on 12 4, 2018

Completed
On planning
On going
Launch
Plan
Project Compound
(Generic name)
Indication Partnered party Discovery Pre-Clin, Clinical Studies NDA Approval Sales Territory Remarks
Phase 1 Phase 2 Phase 3
TM-411 TM-411
(Tamibarotene)
SY-1425 [Syros Pharmaceuticals]
AML
(Acute myelogenous leukemia)
Syros Pharmaceuticals
On going P2 (Multiple drug combination)
USA Combination with azacitidine.Initial data.
AML & MDS (Myelodysplastic syndrome)
On going P2 (Multiple drug combination)
USA Combination with daratumumab.Initial data.
Breast cancer
(BS)
On planning P2
USA Scheduled to start taking into consideration the effectiveness of AML/MDS combination test
TM-411
(Tamibarotene)
OP-09 [Ohara Pharmaceutical]
Neuroblastoma
(NB)
Ohara Pharmaceutical
On going P1/2
Japan
Acute promyelocytic leukemia
(APL)
Toko Pharmaceutical Industrial
NDA
China
Neutropenia
(NP)
-
Completed
USA

Subsidiary

Updated on 12 15, 2018

Company name
TMRC Co., Ltd.
RaQualia Innovations Inc.

Because of the personal survey, there are cases where the information on this site is "different from the fact" due to business content change or misunderstanding etc.
Therefore, please do not use for investment judgment. Also, this site is not intended to solicit investment.

Advertisements